(Q46423506)

22 December 2017

title

How effective is risedronate in preventing bone loss in patients on high-dose steroids? (English)

1 reference

22 December 2017

author name string

Asma Arabi

series ordinal

1

1 reference

22 December 2017

Ghada El-Hajj Fuleihan

series ordinal

2

1 reference

22 December 2017

publication date

19 August 2008

1 reference

22 December 2017

Nature Clinical Practice Endocrinology and Metabolism

published in

1 reference

22 December 2017

volume

4

1 reference

22 December 2017

issue

10

1 reference

22 December 2017

page(s)

540-541

1 reference

22 December 2017

The epidemiology of glucocorticoid-associated adverse events

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0923

7 January 2021

Glucocorticoid-induced osteoporosis: pathophysiology and therapy

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0923

7 January 2021

Risedronate for prevention of bone mineral density loss in patients receiving high-dose glucocorticoids: a randomized double-blind placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0923

7 January 2021

Prevention and treatment of glucocorticoid-induced osteoporosis: a comparison of calcitriol, vitamin D plus calcium, and alendronate plus calcium.

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0923

7 January 2021

Teriparatide or alendronate in glucocorticoid-induced osteoporosis

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0923

7 January 2021

Oral bisphosphonate-induced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention, and treatment

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0923

7 January 2021

Identifiers

DOI

10.1038/NCPENDMET0923

1 reference

22 December 2017

PubMed ID

18711408

1 reference

22 December 2017